Michael Pinsky, MD
Urology · Covington, LANPI 1164749909
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.2%), travel and lodging and education — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Neotract Inc. at 33.3% of the total. Reporting peaked in 2019 at $4,230 and has fallen 81.9% since, to $764 in 2025.
Across 154 payments — averaging $53.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neotract Inc.$3K
- Teleflex LLC$1K
- Cook Medical LLC$1K
- Cook Incorporated$677
- Myriad Genetic Laboratories, Inc.$325
- Astellas Pharma US Inc$295
- plus $2K from 23 others
What the payments were for
- Travel & lodging$3,49142%
- Food & beverage$4,72157%
- Education$350%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neotract Inc. | 15 | $2,745 |
| Teleflex LLC | 14 | $1,302 |
| Cook Medical LLC | 47 | $1,230 |
| Cook Incorporated | 3 | $677 |
| Myriad Genetic Laboratories, Inc. | 11 | $325 |
| Astellas Pharma US Inc | 16 | $295 |
| Calyxo, Inc. | 2 | $276 |
| Urogen Pharma, Inc. | 6 | $215 |
| Photocure Inc | 9 | $191 |
| Procept Biorobotics Corporation | 2 | $143 |
| KARL Storz Endoscopy-america | 1 | $138 |
| Sumitomo Pharma America, Inc. | 6 | $122 |
| Intuitive Surgical | 1 | $99 |
| Boston Scientific | 2 | $97 |
| Hollister Incorporated | 3 | $53 |
| Pfizer | 2 | $46 |
| Johnson & Johnson | 1 | $36 |
| AstraZeneca | 1 | $35 |
| Progenics Pharmaceuticals, Inc. | 1 | $34 |
| Endo Pharmaceuticals Inc. | 2 | $32 |
| Merck | 1 | $27 |
| Smith+Nephew | 1 | $19 |
| Ferring Pharmaceuticals Inc. | 1 | $19 |
| Bayer | 1 | $18 |
| Civco Medical Instruments | 1 | $18 |
| Olympus America Inc. | 1 | $16 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $14 |
| Coloplast | 1 | $13 |
| Urovant Sciences Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$3,272
- Cook Medical Dilation/Access$598
- Cook Medical Urology$288
- CVAC Aspiration System$276
- Barrigel$161
- Cook$149
- CUTTING LOOP, BIPOLAR, 24/26 FR.$138
- AQUABEAM SYSTEM$122
- JELMYTO$117
- Cook Medical Perc Sets$100
How this compares
$8,247 in reported general payments places this provider in the 80th percentile of 199 urology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 79 | $49,800 |
| MyrbetriqMirabegron | 27 | $14,515 |
| Tamsulosin Hcl | 700 | $6,186 |
| Solifenacin Succinate | 72 | $2,561 |
| Finasteride | 149 | $1,229 |
| CefuroximeCefuroxime Axetil | 81 | $1,164 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 65 | $918 |
| Ciprofloxacin Hcl | 251 | $663 |
| Oxybutynin Chloride ErOxybutynin Chloride | 26 | $466 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 102 | $362 |
| Potassium Citrate ErPotassium Citrate | 11 | $182 |
| Ampicillin Trihydrate | 13 | $152 |
| Doxycycline Hyclate | 15 | $141 |
| Methylprednisolone | 18 | $127 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $122 | $49,80079 claims |
| Astellas Pharma US IncMyrbetriq | $295 | $14,51527 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 199 urology providers in Louisiana.
Other urology in Covington
- Sunil PurohitCovington$99K
- Joshua SleeperCovington$11K
- Richard VanlangendonckNew Orleans$289K
- Gerard HenryBossier City$256K
- Ralph HendersonShreveport$211K
- Wayne HellstromNew Orleans$183K
- Colin GoudelockeNew Orleans$124K
- Raju ThomasNew Orleans$67K
- Louis KraneNew Orleans$62K
- Kevin HebertShreveport$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.